<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01678898</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F01</org_study_id>
    <nct_id>NCT01678898</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients</brief_title>
  <official_title>A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first human treatment with PRX-102, an enzyme being developed as a long-term
      enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha
      galactosidase deficiency). The safety, tolerability, and exploratory efficacy will be
      evaluated in this study of increasing doses. Patients will be treated with infusions every
      two weeks for 12 weeks (7 infusions).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reportings of adverse events reported by the patient and from monitoring with clinical laboratory, physical examination and ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gb3 concentrations</measure>
    <time_frame>12 weeks</time_frame>
    <description>Gb3 concentrations in plasma and urine sediment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of glomerular filtration and proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Short term brief pain inventory</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 0.2 mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 1 mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 2 mg/kg every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-102</intervention_name>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_label>2 mg/kg</arm_group_label>
    <other_name>plant cell expressed recombinant human alpha-galactosidase-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic adult Fabry patients (≥18 yrs)

          -  Males: plasma and/or leucocyte alpha galactosidase activity (by activity assay) less
             than lower limit of normal (LLN in plasma=3.2 nmol/hr/ml, LLN in leucocytes=32
             nmol/hr/mg/protein)

          -  Females: historical genetic test results consistent with Fabry mutations

          -  Globotriaosylceramide (Gb3) concentration in urine &gt; 1.5 times upper normal limit

          -  Patients who have never received enzyme replacement therapy (ERT) in the past, or
             patients who have not received ERT in the past 6 months and have a negative anti alpha
             galactosidase antibody test

          -  eGFR ≥ 60 mL/min/1.73m2

          -  The patient signs informed consent

          -  Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically acceptable method of contraception, not including the rhythm
             method

        Exclusion Criteria:

          -  Participation in any trial of an investigational drug within 30 days prior to study
             screening

          -  Chronic kidney disease stages 3-5 (CKD 3-5) (Appendix 7)

          -  History of dialysis or renal transplantation

          -  Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
             therapy initiated or dose changed in the 4 weeks prior to screening

          -  Severe myocardial fibrosis by MRI (≥2 late-enhancement [LE] positive left ventricular
             segments) (Weidemann et al. 2009)

          -  History of clinical stroke

          -  Pregnant or nursing

          -  Presence of HIV and/or HBsAg and/or Hepatitis C infections

          -  Known allergies to ERT

          -  Known allergy to Gadolinium based contrast agents

          -  Presence of any medical, emotional, behavioral or psychological condition that, in the
             judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Almon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Human Genetics, Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Baylor Institute of Metabolic Disease</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O &amp; O Alpan LLC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Victoria</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Clinical Research Private Institute</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Quiron Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Paraguay</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2012</study_first_submitted>
  <study_first_submitted_qc>September 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>Alpha galactosidase deficiency</keyword>
  <keyword>Metabolic storage disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

